Search results
Is Bio-Rad Laboratories (BIO) Significantly Undervalued? An In-depth GF Value Analysis
GuruFocus.com via Yahoo Finance· 10 months agoOn August 4, 2023, Bio-Rad Laboratories Inc (NYSE:BIO) saw a daily gain of 3.5%, despite a reported...
Unveiling Bio-Rad Laboratories (BIO)'s Value: Is It Really Priced Right? A Comprehensive Guide
GuruFocus.com via Yahoo Finance· 9 months agoBio-Rad Laboratories Inc (NYSE:BIO) has seen a daily loss of 1.42% and a 3-month loss of 1.26%, with...
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?
Simply Wall St. via Yahoo Finance· 2 years agoLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is...
Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?
Zacks via Yahoo Finance· 11 months agoBio-Rad Laboratories, Inc. BIO is set to release second-quarter 2023 results on Aug 3 after the...
Is Now An Opportune Moment To Examine Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Simply Wall St. via Yahoo Finance· 5 months agoBio-Rad Laboratories, Inc. (NYSE:BIO), might not be a large cap stock, but it led the NYSE gainers...
Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings Estimates
Zacks via Yahoo Finance· 2 years agoBio-Rad (BIO) delivered earnings and revenue surprises of 0.39% and 1.34%, respectively, for the...
Is It Time To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?
Simply Wall St. via Yahoo Finance· 1 year agoToday we're going to take a look at the well-established Bio-Rad Laboratories, Inc. (NYSE:BIO). The...
Bio-Rad Laboratories (BIO) Dips More Than Broader Markets: What You Should Know
Zacks via Yahoo Finance· 12 months agoBio-Rad Laboratories (BIO) closed at $376.56 in the latest trading session, marking a -0.66% move...
Investors Aren't Entirely Convinced By Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Revenues
Simply Wall St. via Yahoo Finance· 6 months agoWith a median price-to-sales (or "P/S") ratio of close to 3.9x in the Life Sciences industry in the...
Bio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoBio-Rad's (BIO) Clinical Diagnostics segment is expected to report growth in Q2, driven by its focus...